Kazan medical journalKazan medical journal0368-48142587-9359Eco-Vector559010.17750/KMJ2016-492Research ArticleEvaluation of the relationship between concentration of endothelin-1 and magnesium in the blood and the severity of ischemic heart diseaseAbdullayevR Fgulnazdadashova@mail.ruBakhshalievA Bgulnazdadashova@mail.ruGulievaA Dgulnazdadashova@mail.ruHuseynzadeR Rgulnazdadashova@mail.ruScientific-Research Institute of Cardiology named after J. AbdullayevAzerbaijan Medical University1508201697449249618112016Copyright © 2016, Abdullayev R.F., Bakhshaliev A.B., Gulieva A.D., Huseynzade R.R.2016<p><strong>Aim.</strong> To study the relationship between concentrations of endothelin-1 and magnesium in blood depending on functional class and old myocardial infarction in patients with stable angina.</p><p><strong>Methods.</strong> The study included 58 patients with ischemic heart disease, II and III functional class stable angina. 19 of these patients suffered a myocardial infarction in the past. The control group consisted of 25 healthy volunteers. Endothelin-1 level in blood serum was determined by enzyme immunoassay, the concentration of magnesium by colorimetric method.</p><p><strong>Results.</strong>Endothelin-1 level in the general group of patients with stable angina was 1.28±0.23 fmol/ml and was significantly higher than that of control group (0.52±0.13 fmol/ml, p</p><p><strong>Conclusion.</strong> In patients with II-III functional class stable angina statistically significant increase in level of endothelin-1 and a decrease in the concentration of magnesium in blood serum compared with the control group was revealed; a negative correlation between endothelin-1 and magnesium levels in the blood, which is characterized by increasing the degree of correlation depending on the severity of the ischemic heart disease clinical form was established.</p>stable anginaendothelial dysfunctionendothelin-1magnesiumстабильная стенокардия напряжениядисфункция эндотелияэндотелин-1магний[Бабушкина Н.В., Сергеева А.С., Пивоваров Ю.Н. и др. Структурные и функциональные особенности сосудистого эндотелия. Кардиология. 2015; (2): 82-86.][Гомазков О.А. Эндотелин в кардиологии: молекулярные, физиологические и патологические аспекты (обзор). Кардиология. 2001; (2): 50-58.][Спасов А.А., Харитонова М.В., Иежица Н.Н. и др. Функциональные резервы сердца в условиях алиментарного дефицита магния. Кардиология. 2012; (10): 39-44.][Соколов Е.И., Гришина Т.Н., Штин С.Р. Влияние фактора Виллебранда и эндотелина-1 на формирование тромботического статуса при ишемической болезни сердца. Кардиология. 2013; (3): 25-30.][Шилов А.М., Святов И.С., Кравченко В.В. и др. Применение препаратов магния для профилактики нарушений ритма сердца у больных острым инфарктом миокарда. Рос. кардиол. ж. 2002; (1): 16-19.][Balliqand J.L. New mechanisms of LDL - cholesterol induced endothelial dysfunction; correction by statins. Bull. Mem. Belq. 2002; 157: 427-431.][Berthon N., Laurant P., Hayoz D. et al. Magnesium supplementation and deoxycorticosterone acetate - salt hypertension: effect on arterial mechanical properties and activity of endothelin-1. Can. J. Physiol. Pharmacol. 2002; 80: 553-561. http://dx.doi.org/10.1139/y02-082][Daviqnon J., Ganz P. Role of endotyelial dysfunction in atherosclerosis. Circulation. 2004; 109 (III): 27-32.][Khan I.A. Role endothelin-1 in acute myocardial infarction. Chest. 2005; 127: 1474-1476. http://dx.doi.org/10.1378/chest.127.5.1474][Kupetsky-Rincon E.A., Uitto J. Magnesium: novel applications in cardiovascular disease - a review of the literature. Ann. Nutr. Metab. 2012; 61: 102-110. http://dx.doi.org/10.1159/000339380][Laurant P., Kantelip J.P., Berthelot A. Dietary magnesium supplementation modifies blood pressure and cardiovascular function in mineralocorticoid - salt hypertensive rats but not in normotensive rats. S. Natur. 1995; 125: 830-841.][Negrusz-Kawchka M. The role of endothelins in human cardiovascular disease. Pol. Merkuriusz. Lek. 2001; 11: 444-446.][Omland T., Lie R.T., Aarsland T., Dickstein K. Plaimaendothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation. 1994; 89: 1573-1579. http://dx.doi.org/10.1161/01.CIR.89.4.1573][Rosanoff A., Plesser M.R. Oral magnesium supplements decrease high blood pressure (SBP 3155 mm Hg) in hypertensive subjects on anti-hypertensive medications: a targeted meta-analys. Magnes. Res. 2013; 26: 93-99.][Rokan R., Hofmann P., van Duvillard S.P. et al. Oral magnesium therapy, exercise heart rate, exercise tolerance, and myocardial function in coronary artery disease patients. Br. J. Sports Med. 2006; 40 (9): 773-778. http://dx.doi.org/10.1136/bjsm.2006.027250][Shechter M., Sharir M., Labrador M.S. et al. Oral magnesium therapy improves endothelial function in patients with coronary artery disease. Circulation. 2000; 102: 2353-2358. http://dx.doi.org/10.1161/01.CIR.102.19.2353][Schuitemaker G.E., van der Pol G.A., Aretz C.P., Dinant G.J. A placebo-controlled, double-blind, randomized trial of magnesium-pyridoxal-5’-phosphate-glutamate for hypercholoterolaemia and other clinical-chemical risk factors of cardiovascular disease in a primary care setting. Eur. J. Clin. Pharmacol. 2001; 56: 857-863. http://dx.doi.org/10.1007/s002280000247][Ueshima K. Magnesium and ishemic heart disease: a review of epidemiological experimental and clinical evidences. Magnes. Res. 2005; 18: 275-284.][Zolk O., Qattek J., Sitzler G. et al. Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure. Circulation. 1999; 99: 2118-2123. http://dx.doi.org/10.1161/01.CIR.99.16.2118]